22.02.2019 14:00

Daiichi Sankyo Shifts Several Top Leaders to New Roles for Company's Launch into its Next Growth Phase


TOKYO and MUNICH and BASKING RIDGE, N.J., Feb. 22, 2019 /PRNewswire/ -- Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced senior-level organizational changes to oversee the realization of the company's long-term vision and strategic priorities, which include delivering seven distinct new molecular entities in oncology by 2025, as well as specialty medicines that change the standard of care. 

Junichi Koga, PhD will become the new global Head of R&D Unit, drawing from his deep expertise in bioengineering and biologics research and development. Dr. Koga, currently Senior Executive Officer and Head of the R&D Division in Japan, will assume his new role on April 1, 2019 and will relocate to the company's U.S. site in Basking Ridge, New Jersey. He will co-chair the Daiichi Sankyo Global Executive Meeting of Research and Development (GEMRAD), the top decision-making body in R&D, together with Antoine Yver, MD, the Head of Oncology R&D.

Glenn Gormley, MD, PhD will successfully complete his term as global Head of R&D Unit, Senior Executive Officer of Daiichi Sankyo Company, Limited and President and CEO of Daiichi Sankyo, Inc. (the company's U.S. affiliate) on March 31, 2019. He will remain at the company as Chairman of the Board of Directors of Daiichi Sankyo, Inc. and serve as a special advisor to the company's global Chief Executive Officer Joji Nakayama on R&D matters. 

Also on April 1, 2019, Ken Keller, currently President of Daiichi Sankyo Administrative and Commercial at Daiichi Sankyo, Inc., will take on the expanded role of President and CEO, Daiichi Sankyo, Inc. and will focus on forging even stronger collaboration between R&D and commercial efforts, along with enhancing the company's patient-focused culture. Mr. Keller will also remain in his current role as President & CEO of American Regent, Inc., another U.S.-based Daiichi Sankyo affiliate.

"Close connection between our commercial and R&D organizations in the U.S. and globally will support the next phase of our transformation and growth as a science-based, patient-centered company with a primary focus on oncology," said Ken Keller.  "I look forward to ensuring the insights we get from our customers and patients are woven into the fabric of our entire organization." 

"As of April 1, it will be my honor to lead our global research and development efforts as we accelerate exciting new molecules through the pipeline," said Junichi Koga, PhD. "I look forward to deploying the best science from our global R&D operations to create much needed medicines." 

Junichi Koga, PhD

Dr. Koga started his career in pharmaceuticals in early research after his training in organic chemistry at Kyoto University. He also received his PhD in microbiology from Kyoto Prefectural University of Medicine. In 2009, he joined Daiichi Sankyo in the Pharmaceutical Technology Division, establishing internal capability in biologics, and was later appointed as a corporate officer and Head of Biologics. He became Head of the R&D Division in Japan at Daiichi Sankyo in 2016 and Senior Executive Officer at Daiichi Sankyo in 2018. Prior to joining Daiichi Sankyo in 2009, Dr. Koga led R&D at Amgen's Japan subsidiary.

Ken Keller

Ken Keller joined Daiichi Sankyo, Inc. overseeing commercial operations in May 2014, bringing more than 25 years of pharmaceutical experience with him. Since joining Daiichi Sankyo, Mr. Keller has overseen the dramatic transformation of the U.S. operations from a primary care organization to one poised and ready to succeed in oncology. He also devised and executed the strategies that have led to year-over-year growth of the company's IV iron therapy for iron deficiency anemia by launching into new areas of unmet patient need.

Among his previous career positions, Mr. Keller spent 21 years at Amgen rising through the organization as a respected leader in sales and marketing, general management and joint ventures. At Amgen, he built a $3 billion business unit as well as leading commercialization for four of the world's top selling biologic medicines. 

About Daiichi Sankyo

Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address diversified, unmet medical needs of patients in both mature and emerging markets. With over 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for hypertension and thrombotic disorders, under the Group's 2025 Vision to become a "Global Pharma Innovator with Competitive Advantage in Oncology," Daiichi Sankyo's research and development is primarily focused on bringing forth novel therapies in oncology, including immuno-oncology, with additional focus on new horizon areas, such as pain management, neurodegenerative diseases, heart and kidney diseases and other rare diseases. For more information, please visit: Daiichi Sankyo, Inc., headquartered in Basking Ridge, New Jersey, is a member of the Daiichi Sankyo Group. For more information on Daiichi Sankyo, Inc., please visit:

Kimberly Wix
Daiichi Sankyo, Inc.
+1 908 992 6633 (office)

Cision View original content:

SOURCE Daiichi Sankyo Company, Limited

Börse Stuttgart Anlegerclub

Die richtige Strategie für die Börsenkrise

Stecken Sie nicht den Sand in den Kopf, sondern kaufen Sie die richtigen Aktien. Erfahren Sie im aktuellen Anlegermagazin mehr über attraktive Qualitätsaktien und zyklische Aktien
Kostenfrei registrieren und lesen!

Heute im Fokus

DAX geht tiefrot ins Wochenende -- US-Börsen schließen deutlich im Minus -- Commerzbank-Chef liebäugelt mit Fusion -- Chaos-Brexit vorerst abgewendet -- Nike, Ströer, Uber, Dürr, Hapag im Fokus

Allianz bietet auf Versicherungs-Sparten von BBVA. Nokia-Warnung vor Problemen bei Alcatel-Zukauf sorgen Anleger. ProSiebenSat.1-Aktie vor Mehrjahrestief. Rendite zehnjähriger Bundesanleihen erstmals seit Herbst 2016 wieder negativ. Neuer Videodienst von Apple erwartet. RWE und E.ON im Aufwind.

Die 5 beliebtesten Top-Rankings

Die zehn größten Kapitalvernichter
Hier wurde am meisten Anlegergeld verbrannt
DIe innovativsten Unternehmen
Diese Unternehmen sind am fortschrittlichsten
Die Top-Autos des Genfer Autosalon 2019
Das sind die Highlights
Das hat sich geändert
Diese Aktien hat George Soros im Depot
Diese Aktien hat Warren Buffett im Depot
Einige Änderungen unter den Top-Positionen
mehr Top Rankings


Nun ist es bestätigt: Deutsche Bank und Commerzbank loten offiziell eine Fusion aus. Glauben Sie, dass es tatsächlich dazu kommen wird? Brokerage

Online Brokerage über

Das Beste aus zwei Welten: Handeln Sie für nur 5 Euro Orderprovision* pro Trade unmittelbar aus der Informationswelt von!
Zur klassischen Ansicht wechseln
Kontakt - Impressum - Werben - Pressemehr anzeigen
Top News
Beliebte Suchen
DAX 30
Euro US-Dollar
Deutsche Bank AG514000
Wirecard AG747206
Daimler AG710000
Apple Inc.865985
Scout24 AGA12DM8
Aurora Cannabis IncA12GS7
BMW AG519000
Deutsche Telekom AG555750